DeCure for Frontotemporal dementia and/or amyotrophic lateral sclerosis 6
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for frontotemporal dementia and/or amyotrophic lateral sclerosis 6 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFrontotemporal dementia and/or amyotrophic lateral sclerosis 6 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for frontotemporal dementia and/or amyotrophic lateral sclerosis 6 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
valosin containing protein (VCP) — VCP is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 10QQ · 2.13 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
The 2015 review describes frontotemporal dementia and amyotrophic lateral sclerosis as part of a disease spectrum, with clinical, genetic, and pathological links. Mutations in the same genes are found in patients with FTD, ALS, or FTD/ALS. The review notes that frontotemporal lobar degeneration represents a heterogeneous group of diseases with overlapping clinical symptoms, multiple causative genes, and varying underlying pathology. No drug or treatment is mentioned in this abstract.
A 2024 family case study reports a patient initially diagnosed with schizophrenia whose behavioural variant of frontotemporal dementia was later recognised and confirmed as a definite diagnosis, partly because of a family history of amyotrophic lateral sclerosis. The abstract provides no numbers, no sample size, and no treatment data.
A 1971 abstract on the irreproducibility of properties of compounds such as TiO, TaC, and CdS has no relevance to frontotemporal dementia or amyotrophic lateral sclerosis.
No clinical trial, no drug, no survival or response rate data, and no evidence of any therapeutic intervention for frontotemporal dementia and/or amyotrophic lateral sclerosis 6 appear in these abstracts. What is missing is any trial design, any patient stratification, any funding for treatment studies, and any data on whether any compound alters the course of either disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neuropathology and Applied Neurobiology · 2015 · 229 citations
Review: An update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations
AbstractThe development of our understanding of frontotemporal dementia (FTD) has gathered pace over the last 10 years. After taking a back seat to Alzheimer's disease for many years FTD has emerged as a significant group of heterogeneous diseases often affecting people under the age of 65. FTD has also been brought into the spotlight as the major disease entities of the group have clinical, genetic and pathological links to motor neuron disease/amyotrophic lateral sclerosis, indicating that they form a disease spectrum. In this review, we overview how the pathological concept of frontotemporal lobar degeneration (FTLD) and the clinical concept of FTD evolved and show that FTLD, once thought of as a single disorder, represents a heterogeneous group of diseases with overlapping clinical symptoms, multiple causative genes and varying underlying pathology. We also provide a brief summary of the clinical manifestations, summarize the major genetic aspects and describe the main pathological features seen in the different subtypes of FTLD. We also summarize the correlations that exist between clinical presentations and pathological variants. An overview of the main pathogenic mechanisms is also provided.
IRREPRODUCIBILITY OF THE PROPERTIES OF COMPOUNDS OF VARIABLE COMPOSITION SUCH AS TiO, TaC, AND CdS.
AbstractFrontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are considered to be part of a spectrum. Clinically, FTD patients present with dementia frequently characterized by behavioral and speech problems. ALS patients exhibit alterations of voluntary movements caused by degeneration of motor neurons. Both syndromes can be present within the same family or even in the same person. The genetic findings for both diseases also support the existence of a continuum, with mutations in the same genes being found in patients with FTD, ALS, or FTD/ALS.
Neurology Bulletin · 2024 · 0 citations · open access
Clinical spectrum of frontotemporal dementia: schizophrenia-like symptoms and amyotrophic lateral sclerosis (family case study)
AbstractFrontotemporal dementia is a heterogeneous pathology with various clinical, histological, and genetic variants. The behavioral variant of frontotemporal dementia (bvFTD) in some cases presents differential diagnostic difficulties when distinguishing from primary mental disorders. The article provides an observation of patient K., who was observed at the initial stage of the disease with a diagnosis of schizophrenia. The comparison of psychopathological and behavioral symptoms with the presence of a family history of amyotrophic lateral sclerosis (ALS) served as a turning point to a different interpretation of the pathology and recognition and confirmation of the “definite diagnosis” — bvFTD.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
